Clinical Trial Update: An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. [Phase 3]

View source ↗

Summary

Open-label Phase 3b trial of ivosidenib plus azacitidine in IDH1-mutant acute myeloid leukemia patients ineligible for intensive chemotherapy. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tibsovo (ivosidenib)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Servier Affaires Médicales | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: RECRUITING